We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

Fund managers haven’t disclosed any holdings of OKUR yet.

OKUR Hedge Fund Activity: Q1 2026 in Review

51 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2026, worth a combined $114M — up 256% from $32M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new OKUR positions and 9 closed out — a net gain of 9 holders — while 12 added to existing stakes and 14 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12.3M. The largest seller was Shay Capital, cutting an estimated $2M.

  • 51 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2026, up from 44 in Q4 2025.
  • Funds reported $114M of OnKure Therapeutics stock for Q1 2026, up 256% quarter-over-quarter.
  • 18 funds opened new OnKure Therapeutics positions in Q1 2026 and 9 closed out, a net change of +9 holders.
  • The largest OnKure Therapeutics buyer in Q1 2026 was RA Capital Management, an estimated $12.3M added.
  • The largest OnKure Therapeutics seller in Q1 2026 was Shay Capital, an estimated $2M sold.

Based on aggregated 13F filings for Q1 2026.